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 Abstract 
 7,8-dihydroxyflavone (7,8-DHF), which is a member of the flavonoid family, is a selective 
tyrosine kinase receptor B (TrkB) agonist that has neurotrophic effects in various neurological 
diseases such as ischemic stroke and Parkinson’s disease [3]. In this study, we assessed the 
angiogeneic effect of 7,8-DHF in endothelial cells derived from resistance vessel of the brain. 
Angiogenesis by 7,8-DHF is an important factor that helps prevent and treat various ischemic 
diseases. In this study, we found that rat RV cells used in the experiment possess the TrkB 
receptor. Our data also demonstrates that 7,8-DHF is able to stimulate cell proliferation in RV 
cells, suggesting that 7,8-DHF is capable of inducing angiogenesis. The 7,8-DHF activates the 
TrkB receptor which then leads to cell proliferation. In our study we also showed the effects of 
7,8-DHF in the presence of the TrkB inhibitor cyclotraxin-B. Addition of cyclotraxin-B blocked 
the TrkB receptor and counteracted the effects of 7,8-DHF.  Cell proliferation occurs in RV cells 
with the addition of 7,8-DHF, but this proliferation is inhibited by cyclotraxin-B . 
 
 
 
 
 
 
 
 
 
Introductions 
Flavonoids are part of a large family of polyphenolic compounds that are found in high 
concentrations in both fruits and vegetables [4].  A variety of studies have clearly demonstrated 
that flavonoids such as 3,6-dihydroxyﬂavone, 3,7-dihydroxyﬂavone, 5,6,7-dihydroxyﬂavone and 
3,5,7-dihydroxyﬂavone shield against neuronal cell death, augment existing neuronal function, 
and promote neuronal regeneration [11]. 7,8-dihydroxyflavone (7,8-DHF) is an example of one 
of these flavanoids that has neurotrophic activities in various neurological diseases such as 
stroke and Parkinson's disease [6]. In a recent study, 7,8-DHF was shown to be a mimic of brain-
derived neurotrophic factor (BDNF) as well as a selective tyrosine kinase B (TrkB) receptor 
agonist.  BDNF is a cognate ligand of the TrkB receptor; BDNF-induced activation of these 
receptors results in neuronal survival, neuronal differentiation, and neurogenesis in a variety of 
disorders including stroke, amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s 
disease [10].  
Ischemic cardiovascular and cerebrovascular disorders resulted from atherosclerosis-
associated arterial infarction are leading causes of death in Western society. The functional 
recovery of the ischemic tissues and organs is dependent on re-establishing collateral networks 
that sufficiently supply hyper-oxygenated blood to specialized cell populations. In response to 
ischemic insults, most tissues in the body have extraordinary capabilities to compensate low 
levels of oxygen by mechanisms of vasodilation, angiogenesis, arteriogenesis, vascular 
remodeling and hematopoiesis [3]. This study primarily focuses on the benefits and applications 
of angiogenesis, the formation of new vessels that is caused by the sprouting of endothelial cells 
from preexisting vessels.  
The process of angiogenesis occurs after cerebral ischemia, or brain injury from severe 
reduction of blood supply to the brain [7].  Ischemia occurs in a wide range of pathologic 
processes and is the focus of much research involving strokes and other diseases.  The role of 
ischemia in pathophysiology is different in each case, and stimulating angiogenesis can help 
treat disease in some cases [5]. The main purpose of this study is to determine whether 7,8-DHF 
can stimulate angiogenesis, which would be beneficial to stroke patients.   
Specifically, we examined whether 7,8-DHF is able to stimulate cell proliferation and 
calculated a dose-response curve.  We also conducted a study using an inhibitor of 7,8-DHF and 
an inhibitor of BDNF.  This study used RV cells, which are rat brain derived endothelial cells. In 
our study, we hypothesized that 7,8-DHF can induce cell proliferation in RV cells.  
 
Methods and Materials 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2(4-sulfophenyl)2-H-          
tetrazolium, inner salt (MTS) came from Promega Corporation (Madison, WI, USA). 7,8-
dihydroxyfalvone was purchased from TCI America (Portland, OR). Dulbecco’s modified 
Eagle’s Medium (DMEM), fetal bovine serum, trypsin, and Penicillin-Streptomycin Solution 
were all obtained from Gibco Company. TrkB antibody was purchased from BD Biosciences. 
Beta-tubulin antibody was purchased from Cell Signaling Technology Inc. Enhanced 
chemiluminescence system was purchased from Thermo Corporation. AlphaEase Image 
Analysis Software was obtained from Alpha Innotech Corp.  
 
The RV Cell Line 
 Rat brain derived endothelial cells (a generous gift from Dr. Diglio Clement, Department of 
Pathology, Wayne State University) were maintained in DMEM containing 10% fetal bovine 
serum (FBS) and were grown on tissue culture dishes or plates. 
 
Cell Viability Assay 
Cell viability was determined by the ability of the viable cells to metabolize 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2(4-sulfophenyl)2-H-tetrazolium, inner salt 
(MTS), which was described previously [13]. Prior to this, the RV cells were plated in 96-well 
plates, left to attach for 5 hours, and then the experimental doses of 7,8-DHF were added. 
Following the indicated experimental treatments, the RV cells were cultured overnight and 10 μL 
MTS solution was added to the cells the next day.  After 3 hour incubation at 37° C, absorbance 
at 490 nm was then measured by a Thermo plate reader. The cells that were left untreated were 
considered as the controls, and the growth medium devoid of cells in the presence of MTS 
solution was used as the solution background. Cell viability was presented as a percentage of the 
untreated controls. For the MTS assay, there were eight samples in each group. 
 
Inhibitor cyclotraxin-B 
 Cyclotraxin-B is the first highly potent and selective TrkB inhibitor that displays anxiolytic 
properties in mice. Cyclotraxin-B allosterically alters the conformation of TrkB, which leads to 
the inhibition of both the BDNF-dependent and –independent (basal) activities. Studies have 
shown that cyclotraxin-B might not only be a potent tool in investigate the role of BDNF and 
TrkB in pathology and physiology, but it also represents a lead compound for the development of 
new therapeutic approaches to treat brain disorders [2]. 
 
 
Inhibitor Study 
Another study was run to determine the effects of cyclotraxin-B on the experimental 
doses of DHF and BDNF. The experimental doses that were used in this research were the 
control, 5μM cyclotraxin-B, 4 nM BDNF, 4 nM BDNF + 5μM cyclotraxin-B, 100 nM DHF, and 
100 nM DHF + 5μM cyclotraxin-B. The doses were added and the RV cells were cultured 
overnight and 10μL MTS solution was added to the cells the next day. After 3 hour incubation at 
37℃, absorbance at 490nm was then measured by a Thermo plate reader. The cells that were left 
untreated were considered the controls, and the growth medium devoid of cells in the presence 
of MTS solution was used as the solution background. Cell viability with the presence of 
cyclotraxin-B was compared with the viability of the cells with the experimental dose and 
expressed in the form of a percentage. For the MTS assay, there were eight samples in each 
group. 
 
Western Blot Analysis 
Proteins were subjected to electrophoresis in Tris-glycine sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (10%) and electrotransferred to nitrocellulose membrane.  
The blots were then incubated with primary antibody against TrkB at 4°C overnight. After 
washing, the blots were incubated with horseradish peroxidase-conjugated secondary antibody 
for 1 hour. Blots were developed with the enhanced chemiluminescence system and were 
captured on Kodak autoradiographic films.  Beta-tubulin was also detected as a loading control. 
 
Statistical evaluation 
All of the values that were reported were expressed as mean ± SEM.  Statistical differences 
among groups were tested by one-way ANOVA, followed by Bartlett’s test for homogeneity of 
variances. The value p < 0.05 was considered statistically significant. 
 
RESULTS 
 
7,8-DHF Induces Cell Proliferation 
in a 96 well plate of RV cells containing 2000 cells. The cells were first maintained in DMEM 
containing 10% FBS and were grown on tissue culture plates.  The cells were allowed to grow 
and attach for 5 hours.  The experimental doses of 7,8-DHF were then added.  The cell culture 
dish that was the least confluent was used in the experiment.  The remaining surface medium 
was vacuumed out of the dish, the cells were washed with DPBS solution, and then 2 ml of 
TrypLE Express (trypsin) was added to remove the attached cells from the surface of the dish. 
Once the cells became unattached, 8 ml of DMEM containing 10% FBS was added to cease the 
trypsin’s effect. The cells were then quantified via light microscope and the correct concentration 
of both the cells and medium were determined and then combined into a preparatory dish. The 
cells were then plated into a 96 well plate containing 2000 of the RV cells. Once the cells had 
been allowed to incubate for 5 hours, the experimental doses of 7,8-DHF were added to every 
well except the controls. The concentrations of 7,8-DHF started at 5.0 nM and progressed up all 
the way up to 1.0 mM. The cells were then allowed to incubate over night (24 hours) and were 
then quantified the next day. 
  To investigate if 7,8-DHF would induce cell proliferation, we conducted a dose-response 
study of 7,8-DHF as described above. Cell viability was measured by the MTS assay. 7,8-DHF 
induced cell proliferation at every concentration except 5.0 nM and 50 nM, with the higher doses 
having the greatest effect (Figure 1). There were two distinct peaks of cell proliferation, one at 
1.0 and the other at 0.5 mM. The results shown in this dose-response study clearly demonstrate 
that 7,8-DHF has a positive effect on the proliferation of RV cells. 
 
Figure 1. The cell proliferation effects of 7,8-DHF on RV cells. The cells were plated in a 96-well plate and all 
were treated with experimental doses of 7,8-DHF except for the control. The results were obtained via the cell 
viability assay using MTS. The increasing concentrations are used in order to determine the effects of the 
dose size on cell proliferation, thus creating a dose curve. *p< 0.01, versus control group. 
Both BDNF and 7,8-DHF are Inhibited by Cyclotraxin-B 
 In our inhibitor study, the control group contained untreated RV cells and was compared 
against other cells that were treated with specific experimental doses along with cells that were 
just treated with 5 μM of the inhibitor cyclotraxin-B. One set of cells was treated with 4 nM of 
BDNF and compared against another set that contained the original 4 nM of BDNF as well as 5 
μM of cyclotraxin-B. In the other set of cells that were compared against one another, one group 
contained 100 nM of DHF and was compared against another that group that contained both 100 
nM DHF and 5 μM of cyclotraxin-B.  
 In the inhibitor study, the BDNF and the 7,8-DHF groups were compared to the control 
group; both groups showed cell proliferation.  BDNF and 7,8-DHF cells that were treated with 
cyclotraxin-B did not show this cell proliferation (Figure 2).   
 
 
Figure 2. The inhibitive effects of cyclotraxin-B on both BDNF and DHF. The cells were plated in a 96-well 
plate and were treated with different experimental doses. The control was left untreated, the BDNF and the 
BDNF+cyclotroxin-B were compared, and the 7,8-DHF and the 7,8-DHF+cyclotraxin-B were compared. The 
results were obtained via the cell viability assay using MTS. This figure clearly demonstrated the differences 
between the control and BDNF and 7,8-DHF, along with the visible differences between the 7,8-DHF and its 
inhibited counterpart, and the BDNF and its inhibited counterpart. 
a
p< 0.01, versus control group. 
 
 
Western Blot Analysis Confirms the Presence of TrkB Receptor in RV Cells 
 Western blot analysis confirmed the presence of the TrkB receptor in RV cells (Figure 3).  
This suggests that the 7,8-DHF activates the receptor, which then leads to the cell proliferation.  
It also suggests that cyclotraxin-B inhibits the receptor is inhibited, which prevents the cell 
proliferation. 
  
Figure 3. Western blot showing the presence of TrkB in the RV cells. The β-tublin is the loading control and 
the TrkB is the receptor that is shown to be found in the rat brain derived endothelial cells. 
 
Discussion 
 Researchers have recently been focusing on counteracting the adverse effects of ischemia 
by inducing angiogenesis. In this study, we demonstrated that 7,8-DHF can induce angiogenesis. 
Past studies have shown that 7,8-DHF is a selective TrkB agonist and BDNF mimic that may 
provide neuroprotection in different diseases models via anti-oxidative activity and TrkB agonist 
activity [5]. TrkB, which is the most abundant Trk receptor that is expressed in the 
central nervous system, is mainly activated by BDNF and NT4/5 [3]. In this study, we showed 
that it is not the antioxidant activity of 7,8-DHF that causes cell proliferation, but rather its 
ability to mimic BDNF and activate the TrkB receptor. This study as a whole suggests that the 
use of the 7,8-DHF as a mimic to the protein BDNF can lead to TrkB activation and cell 
proliferation.  
 There are two adjacent hydroxyl (-OH) groups in the structure of 7, 8-DHF and hydroxyl 
groups are thought to confer antioxidant activity.  As such the structure of 7, 8-DHF itself 
suggested the possibility that 7,8-DHF has anti-oxidant activity [3] (Figure 4). This being said,  
we do not believe that the antioxidant activity is the factor that causes angiogenesis due to the 
TrkB receptor activation by 7,8-DHF. The results of this study confirm this possibility. 
 Figure 4. Structure of 7,8-dihydroxyflavone. This figure demonstrates the organic structure of 7,8-DHF. The 
two adjacent hydroxyl (-OH) groups in the structure are thought to confer the antioxidant activity. 
 
 Flavonoids belong to a group of natural substances with variable phenolic structures and are 
found in fruit, vegetables, grains, bark, roots, stems, flowers, tea, and wine [8]. These natural 
products were known for their beneficial effects on health long before flavoniods were isolated 
as the effective compounds. More than 4000 different varieties of flavonoids have been 
identified, many of which are responsible for the attractive colors of flowers, fruit, and leaves. 
The research on flavonoids received an added impulse with the discovery of the French paradox, 
i.e., the low cardiovascular mortality rate observed in Mediterranean populations in association 
with red wine consumption and a high saturated fat intake. Furthermore, epidemiologic studies 
suggest a protective role of dietary flavonoids against coronary heart disease [9]. 
 Multiple studies have shown that flavanoids can protect against brain damage and help 
prevent and treat ischemic diseases.  Flavanoids protect neurons against injury induced by 
neurotoxins, suppress neuroinﬂammation, and promote memory, learning and cognitive 
function[13]. This study shows that another beneficial effectse in flavanoids like 7,8-DHF is 
angiogenesis.  This angiogeneic effect suggests that 7,8-DHF could be a potentially promising 
therapeutic intervention for the clinical treatment of neurological diseases such as ischemic 
stroke, Parkinson’s disease and Alzheimer's disease [1]. 
 
 
Conclusion 
 In summary, we showed that 7,8-DHF stimulates angiogenesis and provided evidence that 
this angiogenic effect is mediated the ability of 7,8-DHF to mimic BDNF and activate the TrkB 
receptor. Clinically, inducing angiogenesis could be a promising therapeutic approach to the 
treatment of various neurological diseases.  Many challenges remain, however several large 
trials indicated that delivery of pro-angiogenic factors to patients suffering from myocardial 
infarction and leg ischemia did not confer significant benefits. Despite the success shown in 
animal models, much research needs to be done before pro-angiogenic agents are used clinically 
[1].  
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